Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study

Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study

Background: Bilastine, a novel non-sedating second-generation H1-antihistamine, has been widely used in the treatment of allergic rhinoconjunctivitis and urticaria with a recommended dose of 20 mg once daily in most European countries since 2010. We evaluated its efficacy and safety in Japanese pati...

Full description

Bibliographic Details
Main Authors: Michihiro Hide, Akiko Yagami, Michinori Togawa, Akihiro Saito, Masutaka Furue
Format: Article
Language:English
Published: Elsevier 2017-04-01
Series:Allergology International
Subjects:
Bilastine
Chronic spontaneous urticaria
DLQI
H1-antihistamine
Total symptom score
Online Access:http://www.sciencedirect.com/science/article/pii/S1323893016301113

Similar Items

Similar Items